glp-1 semaglutide for weight loss GLP-1s Researchers identify avenue for enhanced

The most common side effects are gastrointestinal, including nausea (affecting 2040% initially), vomiting, diarrhoea, constipation, and abdominal discomfort

Do not inject cloudy medication

New England Journal of Medicine, 2023

Coverage unavailable when GLP-1 coverable under Part D benefit Beneficiaries who are prescribed Wegovy or Zepbound for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the drug is on the Part D plans formulary (e.g., Zepbound for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, or Wegovy to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease who are either obese or overweight), will not qualify for coverage of that drug under the Bridge Program